Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iC9-CAR.B7-H3 T Cells in Recurrent Platinum-Resistant Epithelial Ovarian Cancer
NCT06305299Phase 1Recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Jul 2024
- Primary completion
- Apr 2036
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iC9-CAR.B7-H3 T cells in epithelial ovarian cancer (EOC), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoints: Toxicity assessed by NCI-CTCAE at 4 weeks, Cytokine Release Syndrome at 4 weeks and 1 more. Started Jul 2024; status: recruiting.
02
Drugs
iC9-CAR.B7-H3 T cells
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT06305299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06305299.